FDA Investigator Kathryn E King
Kathryn E King has conducted inspections on 2 sites in 1 countries as of 27 Oct 2020. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
2
Last Inspection Date:
27 Oct 2020
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Kathryn E King:
Amir Alavi,
Andrew "Drew" Haack, PhD,
Andrew K Haack, PhD,
Anita Narula, PhD,
Arie C Menachem,
Ashar P Parikh,
Barbara Janine Breithaupt,
Bo Chi, PhD,
Brian M Janelsins, PhD,
Carl Lee,
Carolyn A Renshaw,
CDR Donald Ertel,
CDR Ileana Barreto Pettit,
CDR Rochelle B Young, RPh, MSA,
Charles Yuanchia Kuo, PhD,
Chava Kimchi Sarfaty, PhD,
Christopher R Czajka,
Colleen F Hoyt,
David G Eng,
Deborah M Trout,
Henry K Lau,
James R Evans,
Jeffrey M Watson,
Joan Johnson,
Joseph Kutze, PhD,
Keith O Webber, PhD,
Keith Webber, PhD,
Kouros Kangarli,
Lance Mde Souza, MBA,
Laurie Graham,
Linan Ha, PhD,
Lisa K Capron,
Lucila B Nwatu,
Mariza M Jafary,
Marshalette O Edwards,
Michael S Araneta,
Michelle Rfrazier Jessen, PhD,
Mihaly S Ligmond,
Mikhail V Ovanesov, PhD,
Milos Dokmanovic, PhD,
Natalia Pripuzova, PhD,
Nataniel Phillips Sylvain, PhD,
Nicholas L Hunt,
Patricia F Hughes, PhD,
Peter E Baker,
Prabhu P Raju,
Qing Joanna Zhou, PhD,
Rabia Ballica, PhD,
Rebecca Rodriguez,
Reyes Candau Chacon, PhD,
Richard Ledwidge (nmi), PhD,
Riley C Myers, PhD,
Robert D Tollefsen,
Ruth Moore, PhD,
S Lori Brown, PhD MPH,
Scott N Lim,
Sharon K Thoma, PharmD,
Sidney B Priesmeyer,
Stephanie A Slater, MS,
Teegan Dellibovi Ragheb, PhD,
Thomas J Arista,
Thuy T Nguyen, LCDR,
Uttaniti Limchumroon (Tom),
V Teres Speer,
Vanessa Y Gelsey, PhD,
Vanessa Y Jacobs,
Wayne E Seifert,
William V Millar,
Yideng Liang,
Yuan Chia Kuo,
Zhong Li, PhD
Kathryn E King's Documents
Publish Date | Document Type | Title |
---|---|---|
November, 2020 | FDA 483 Response | AGC Biologics, Inc. - Form 483R, 2020-11-23 |
November, 2020 | EIR | AGC Biologics, Inc. - EIR, 2020-11-02 |
November, 2020 | FDA 483 | AGC Biologics, Inc. - Form 483, 2020-11-02 |
March, 2012 | FDA 483 | Genentech, Inc. - Form 483, 2012-03-28 |
June, 2024 | FDA 483 | STgen Bio Co., Ltd. - Form 483, 2024-06-25 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more